Webb5 mars 2024 · The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML. Trovagene Exploring PLK1 Inhibitor in Various Biomarker-Defined Cancer Indications Precision Oncology News Webb14 apr. 2024 · AbstractPurpose:. In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this resistance. Non-luminal breast cancer subtype and high levels of CCNE1 are …
Polo-like kinase-1 is activated by aurora A to promote checkpoint ...
Webbwww.ncbi.nlm.nih.gov Webb27 feb. 2024 · Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several myelodysplastic syndromes and leukemias and is therefore close to clinical translation. The clinical progress of rigosertib has been hampered by a lack of understanding of its … doubletree by hilton st. louis airport mo
PLK1 contributes to autophagy by regulating MYC stabilization in ...
WebbWe identified Polo-like kinase 1 (PLK1), a mitotic kinase, as a resistance mediator whose genomic as well as pharmacological inhibition restored drug sensitivity. Both acquired … Webb28 okt. 2024 · Resistance to oxaliplatin-based chemotherapy represents a significant clinical problem in CRC, resulting in tumor recurrence. Elevated PLK1 expression is … Webb7 dec. 2024 · Inhibition of PLK1 abolished the oncogenic function of HN1L and enhanced the antitumor effect of chemotherapy, which suggests a potential therapeutic strategy … doubletree by hilton stoke